Skip to main content

Eli Lilly Selects Cyntellect s Technology for RNAi Studies

Note: This article has been updated to reflect a factual inaccuracy at the end of the original story, which stated that Cyntellect was a subsidiary of Oncosis.


NEW YORK, Nov. 4 (GenomeWeb News) - Eli Lilly has selected Cyntellect's LEAP technology for high-throughput RNA interference studies, Cyntellect said today.


LEAP, or Laser Enabled Analysis and Processing technology, involves a CCD camera imaging system with mirrors that steer the image in tandem with the cameras, and a laser that then works with the imaging system, according to Cyntellect, of San Diego.


Cyntellect has earlier said it believes this laser-driven method, which it terms optoinjection, is better than other techniques for transfecting RNAi or siRNA into cells because it more efficiently transfects cells than other methods, kills fewer cells, and allows users to transfect one cell but not the adjacent one with the RNA molecules.


The parties did not disclose the financial terms of the agreement.


Cyntellect, a spin-out of moribund stem cell cancer treatment company Oncosis, announced in July that it had received an $183,000 SBIR grant to develop its LEAP platform.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.